Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre

International Journal of Antimicrobial Agents

Volumn 25, Issue 3, 2005, Pages 193-197

  Manno, Graziana ^a,b   Cruciani, Mario ^c   Romano, Luca ^a   Scapolan, Sara ^a   Mentasti, Massimo ^a,b   Lorini, Renata ^a   Minicucci, Laura ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c USL 20   (Italy)

Author keywords

Antimicrobial susceptibility; Antimicrobial use; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DETERMINATION; DRUG USE; DRUG UTILIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STATISTICAL SIGNIFICANCE;

EID: 14344252907     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.11.009     Document Type: Article

References (30)

1. J.R.W. Govan, and V. Deretic Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkolderia cepacia Microbiol Rev 60 1996 539 574
2. G.B. Pier Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction J Infect Dis 151 1985 575 580
3. S.C. FitzSimmons The changing epidemiology of cystic fibrosis J Pediatric 122 1993 1 9
4. K. Mathee, O. Ciofu, and C. Sternberg Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung Microbiology 145 1999 1349 1357
5. O. Ciofu, B. Giwercman, S.S. Pedersen, and N. Hoiby Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonas treatment at the Danish CF center APMIS 102 1994 274 280
6. J.W. Mouton, J.G. den Hollander, and A.M. Horrevorts Emergence of antibiotic resistance among Pseudomonas aeruginosa isolates from patients with cystic fibrosis J Antimicrob Chemother 31 1993 919 926
7. L. Saiman D. Schidlow A. Smith Concepts in care: microbiology and infectious diseases in cystic fibrosis vol. V 1994 Cystic Fibrosis Foundation Bethesda, MD S1
8. J.L. Burns, L. Saiman, and S. Whittier Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients J Clin Microbiol 38 2000 1818 1822
9. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing Proceedings of the ninth informational supplement, Document M100-S9 National Committee for Clinical Laboratory Standards, Wayne, PA 1999
10. B. Frederiksen, C. Koch, and N. Hoiby Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration on pulmonary function in Cystic Fibrosis Pediatr Pulmonol 23 1997 330 335
11. E. Melander, K. Ekdahl, G. Jonsonn, and S. Molstad Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics Ped Infect Dis J 19 2000 1172 1177
12. D.N. Fish, S.C. Piscitelli, and L.H. Danziger Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies Pharmacotherapy 15 1995 279 291
13. D.L. MacLeod, L.E. Nelson, and R.M. Shawar Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment J Infect Dis 181 2000 1180 1184
14. F. Baquero Tak Force of the General Direction for Health Planning of the Spanish Ministry of Health. Antibiotic resistance in Spain: What can be done? Clin Infect Dis 23 1996 819 823
15. J.C. Christenson, E.K. Korgensky, and J.A. Daly In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients J Antimicrob Chemother 45 2000 899 901
16. G. Doring, S.P. Conway, and HG.M. Heijerman Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur Respir J 16 2000 749 767
17. A.S. Prince Biofilms, antimicrobial resistance and airway infection N Engl J Med 347 2002 1110 1111
18. E. Drenkard, and F.M. Ausbel Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation Nature 416 2002 740 743
19. A.S. Bayer, D.P. Spert, and S. Park Functional role of mucoid exopolysaccharide (alginate) in antibiotic induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa Infect Immun 59 1991 302 308
20. D.J. Evans, D.G. Allison, M.R.W Brown, and P. Gilbert Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms towards ciprofloxacin: effect of specific growth rate J Antimicrob Chemother 27 1991 177 184
21. H.R. Stutman, J.C. Akaniro, C.E. Vidaurre, and M.I. Marks In vitro activity of E-1040, a 3-substituted cephalosporins, against pathogens from cystic fibrosis sputum Antimicrob Agents Chemother 34 1990 1366 1427
22. H. Anwar, J.L. Strap, and J.W. Costerton Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy Antimicrob Agents Chemother 36 1992 1347 1351
23. Brown MRW, H. Anwar, and P. Lambert Evidence that mucoid Pseudomonas aeruginosa in the CF lung grows under iron-restricted conditions FEMS Microbiol Lett 21 1984 113 117
24. W.W. Nichols, S.M. Dorrington, M.P. Slack, and H.L. Walmsley Inhibition of tobramycin diffusion by binding to alginate Antimicrob Agents Chemother 32 1988 518
25. M.J. Thomassen, C.A. Demko, B. Boxerbaum, R.C. Stern, and P.J. Kuchenbrod Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis J Infect Dis 140 1979 873 880
26. R.E. Dostal, J.P. Seale, and B.J. Yan Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis Med J Aust 156 1992 662 663
27. W.W. Nichols, M.J. Evans, M.P. Slack, and H.L. Walmsley The penetration of antibiotics into aggregates of mucoid and non mucoid Pseudomonas aeruginosa J Gen Microbiol 135 1989 1291 1303
28. R.M. Shawar, D.L. MacLeod, and R.L. Garber Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob Agents Chemother 43 1999 2877 2880
29. O. Ciofu, V. Fussing, and N. Bagge Characterization of paired mucoid/non mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and riboprinting J Antimicrob Chemother 48 2001 391 396
30. H. Ishida, Y. Ishida, and Y. Kurosaka In vitro and in vivo activities of levofloxacin against biofilm producing Pseudomonas aeruginosa Antimicrob Agents Chemother 42 1998 1641 1645